Filana Therapeutics Inc (FLNA)

$2.09 -0.29 (-12.18%)
Market Cap 191,000.00
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 762,100
Avg Vol 775,998
Day's Range N/A - N/A
Shares Out 955.37M
Stochastic %K 25%
Beta N/A
Analysts Strong Buy
Price Target N/A
Latest News on FLNA
Cassava Sciences says US DOJ has closed investigation into company

Feb 19, 2026, 8:52 AM EST - 20 days ago

Cassava Sciences says US DOJ has closed investigation into company

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 11:51 AM EST - 2 months ago

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Dec 19, 2025, 11:31 AM EST - 2 months ago

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:05 PM EDT - 5 months ago

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Oct 22, 2025, 8:00 AM EDT - 5 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Aug 4, 2025, 7:30 AM EDT - 7 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Jun 30, 2025, 7:00 AM EDT - 9 months ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025, 7:30 AM EDT - 11 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Apr 21, 2025, 4:30 PM EDT - 11 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 26, 2025, 3:49 PM EDT - 1 year ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 10:42 AM EDT - 1 year ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 25, 2025, 8:05 AM EDT - 1 year ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 1 year ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 9, 2025, 10:45 AM EST - 1 year ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 7, 2025, 12:08 PM EST - 1 year ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Feb 3, 2025, 5:45 AM EST - 1 year ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 23, 2025, 2:47 PM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Cassava Sciences Provides a Business Update

Jan 7, 2025, 4:30 PM EST - 1 year ago

Cassava Sciences Provides a Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 23, 2024, 5:45 AM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 18, 2024, 10:53 AM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Dec 13, 2024, 1:16 PM EST - 1 year ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights